Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Transaction in Own Shares 13 April 2026 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 13 April 2026 it purchased the following number of Shares for cancellation. ...
-
Octopus Apollo VCT plc Purchase of Own Securities and Total Voting Rights Octopus Apollo VCT plc (the ‘Company’) announces that on 13 April 2026 the Company purchased for cancellation 19,620,096...
-
NOTICE OF 2026 ANNUAL GENERAL MEETING Shell plc’s 2026 Annual General Meeting (“2026 AGM”) scheduled to be a hybrid meeting, facilitating both physical and virtual attendance Shareholders encouraged...
-
13 April 2026 ICG plc (the “Company”) Transaction in Own Shares The Company announces that in the period from 7 April 2026 to 10 April 2026, in accordance with the terms of its share buyback...
-
13 April 2026 HARGREAVE HALE AIM VCT PLC (the “Company”) NAV announcement As at close of business on 31 March 2026, the unaudited Net Asset Value (“NAV”) for Hargreave Hale AIM VCT plc was as...
-
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY...
-
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY...
-
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY...
-
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY...
-
Media ReleaseCOPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in...